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Background
Nitroxyl (HNO), the reduced and protonated congener of
nitric oxide (NO), is emerging as a novel entity with dis-
tinct pharmacology and therapeutic advantages over NO•
[1]. Importantly, HNO has vasoprotective actions with
the potential to serve as an antioxidant. Here we explored
the ability of HNO to modulate cerebrovascular NADPH
oxidase activity, a major source of superoxide (.O2
-) in the
vasculature.
Materials and methods
Intracranial (pooled middle cerebral and basilar) and
extracranial (carotid) cerebral arteries from male C57BL/
6J mice were treated with angiotensin II (10 nM) acutely
(30 min) and chronically (24 h), respectively, in the
absence and presence of the HNO donor, Angeli's salt
(AS). NADPH (100 μM)-stimulated .O2
- production was
then measured using lucigenin (5 μM)-enhanced chemi-
luminescence.
Results
AS (1 μM) did not scavenge .O2
- generated in a cell free
xanthine (100 μM)/xanthine oxidase (0.05 U/ml) activity
assay (control: 447.9 ± 90.8; AS 507.1 ± 113.3 counts, n =
4). In contrast, acute and chronic treatment with AS
(0.01–1 μM) caused a concentration-dependent decrease
in NADPH oxidase-derived .O2
- production by intracra-
nial and extracranial cerebral arteries, respectively (carotid
0.59 ± 0.05; AS 0.1 μM 0.33 ± 0.08; AS 1 μM 0.16 ± 0.03
103 counts/s/mg, P < 0.05, n = 8). The effects of AS were
reversed by the HNO scavenger, L-cysteine (3 mM) but
unchanged in the presence of the NO￿ scavenger carboxy-
PTIO (200 μM) and sGC inhibitor, ODQ (10 μM).
Conclusion
HNO suppresses vascular NADPH-oxidase activity both
acutely and chronically, possibly via a cGMP-independent
mechanism. Such antioxidant actions of HNO may confer
therapeutic advantages in the treatment of cerebrovascu-
lar disorders.
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